Literature DB >> 10561376

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

R J Gralla1, D Osoba, M G Kris, P Kirkbride, P J Hesketh, L W Chinnery, R Clark-Snow, D P Gill, S Groshen, S Grunberg, J M Koeller, G R Morrow, E A Perez, J H Silber, D G Pfister.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10561376     DOI： 10.1200/JCO.1999.17.9.2971

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  132 in total

Review 1.  Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications.

Authors:  L A Sanchez; M Holdsworth; S B Bartel
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

2.  Cannabinoids for pain and nausea.

Authors:  E Kalso
Journal:  BMJ       Date:  2001-07-07

3.  Nausea and emesis: still an unsolved problem in cancer patients?

Authors:  Jørn Herrstedt
Journal:  Support Care Cancer       Date:  2002-01-31       Impact factor: 3.603

4.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

5.  The importance of clinical practice guidelines (CPGs) for the quality and development of supportive care in Central and Eastern European (CEE) countries.

Authors:  Snezana Bosnjak
Journal:  Support Care Cancer       Date:  2003-10-15       Impact factor: 3.603

Review 6.  Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.

Authors:  Orit Freedman; Eitan Amir; Camilla Zimmermann; Mark Clemons
Journal:  Support Care Cancer       Date:  2011-01-04       Impact factor: 3.603

7.  Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.

Authors:  Rahat Noor; Agop Y Bedikian; Sandy Mahoney; Roland Bassett; Kevin Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Jade Homsi
Journal:  Support Care Cancer       Date:  2012-01-25       Impact factor: 3.603

8.  Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer.

Authors:  Hui-Chun Hsu; Su-Yu Tsai; Shang-Liang Wu; Shiow-Roug Jeang; Mei-Yao Ho; Wen-Shiung Liou; An-Jen Chiang; Tsung-Hsien Chang
Journal:  Support Care Cancer       Date:  2017-06-21       Impact factor: 3.603

9.  Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis.

Authors:  Gary R Morrow; Lee Schwartzberg; Sally Y Barbour; Gianluca Ballinari; Michael D Thorn; David Cox
Journal:  J Community Support Oncol       Date:  2014-07

10.  Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Authors:  Imad Treish; Stacy Shord; John Valgus; Donald Harvey; Jessica Nagy; Jennifer Stegal; Celeste Lindley
Journal:  Support Care Cancer       Date:  2003-06-27       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.